← All trials
NCT05377554
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 29, 2022
- Primary completion
- Jul 1, 2023
- Completion date
- Oct 1, 2023
- First posted
- May 17, 2022
- Last posted
- May 25, 2022
- Enrollment
- 200
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Alume Biosciences, Inc.Lead sponsor
- University of California, San DiegoOverall official - principal investigator
- ErgomedCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.